Introduction: Pujin Biopharmaceutical focuses on the research, development and promotion of biopharmaceuticals, and has successively obtained strategic investments from the National SME Development Fund, Winbond Health (002004) and other parties. The company has the only biopharmaceutical research and development platform in the world that integrates cell drugs and nano-antibody drugs. At present, staged research and development achievements have been achieved, and CAR-T CD 19 products have successfully cured dozens of patients with relapsed and refractory leukemia and malignant lymphoma. As a technical iteration, Purin also successfully applied CAR-T loaded with nano-antibodies to the treatment of solid tumors for the first time in the world.
Legal Representative: Zhang Jishuai
Establishment time: 20 15-07-02
Registered capital: 65,438 yuan+0,630,257 yuan.
Enterprise type: limited liability company
Company address: Room 402, Building 14, Jinhui Road, Kengzi Street, Pingshan District, Shenzhen.